hydroxychloroquine has been researched along with Pulmonary Fibrosis in 8 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The evolution to pulmonary fibrosis is frequent in older males and patients with comorbidities and bone marrow involvement." | 1.56 | First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution. ( Balzarini, L; Ferrozzi, F; Mancini, C; Marvisi, M; Ramponi, S; Uccelli, M, 2020) |
| "One objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long-term rates of organ damage." | 1.48 | Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. ( Magder, LS; Petri, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Perri, G | 1 |
| Marvisi, M | 1 |
| Ferrozzi, F | 1 |
| Balzarini, L | 1 |
| Mancini, C | 1 |
| Ramponi, S | 1 |
| Uccelli, M | 1 |
| Liu, L | 1 |
| Ren, J | 1 |
| He, Z | 1 |
| Men, K | 1 |
| Mao, Y | 1 |
| Ye, T | 1 |
| Chen, H | 1 |
| Li, L | 1 |
| Xu, B | 1 |
| Wei, Y | 1 |
| Wei, X | 1 |
| Petri, M | 1 |
| Magder, LS | 1 |
| Dinwiddie, R | 1 |
| Hacking, D | 1 |
| Smyth, R | 1 |
| Shaw, N | 1 |
| Kokia, G | 1 |
| Carty, H | 1 |
| Heaf, D | 1 |
| Kerem, E | 1 |
| Bentur, L | 1 |
| England, S | 1 |
| Reisman, J | 1 |
| O'Brodovich, H | 1 |
| Bryan, AC | 1 |
| Levison, H | 1 |
| Walker, WC | 1 |
| Wright, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Case-Control Study on the Association Between Periodontal Health and Gingival Crevicular Level of Matrix Metalloproteinase-8 in Post COVID-19 Patients[NCT05950230] | 90 participants (Anticipated) | Observational | 2023-08-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for hydroxychloroquine and Pulmonary Fibrosis
| Article | Year |
|---|---|
The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
Topics: Adenosine Monophosphate; Alanine; Anticoagulants; Antiviral Agents; Biomarkers; Coronavirus Infectio | 2020 |
First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug C | 2020 |
Cholesterol-modified Hydroxychloroquine-loaded Nanocarriers in Bleomycin-induced Pulmonary Fibrosis.
Topics: Animals; Apoptosis; Biomarkers; Bleomycin; Cholesterol; Cytokines; Disease Models, Animal; Drug Carr | 2017 |
Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
Topics: Adult; Antirheumatic Agents; Cardiomyopathies; Cataract; Cohort Studies; Diabetes Mellitus; Disease | 2018 |
Case 3: Assessment: systemic illness and the chest.
Topics: Adrenal Cortex Hormones; Blood Gas Analysis; Diagnosis, Differential; Enzyme Inhibitors; Humans; Hyd | 2000 |
Idiopathic pulmonary fibrosis in infants: good prognosis with conservative management.
Topics: Anti-Inflammatory Agents; Biopsy; Female; Humans; Hydroxychloroquine; Infant; Infant, Newborn; Lung; | 2000 |
Sequential pulmonary function measurements during treatment of infantile chronic interstitial pneumonitis.
Topics: Airway Resistance; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxyc | 1990 |
Diffuse interstitial pulmonary fibrosis and rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Joi | 1969 |